ArticleBritish journal of cancer2012
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01064349 (Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.Breast cancer research : BCR · 2015Pooled it
- Article
- Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran.Iranian journal of medical sciences · 2022Article
- Focal Radiotherapy of Brain Metastases in Combination With Immunotherapy and Targeted Drug Therapy.Deutsches Arzteblatt international · 2021Article
- Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.BMC cancer · 2021Review
- The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.BMC cancer · 2021Article
- Subtype switching in breast cancer brain metastases: a multicenter analysis.Neuro-oncology · 2020Article
- Screening of miRNAs associated with lymph node metastasis in Her-2-positive breast cancer and their relationship with prognosis.Journal of Zhejiang University. Science. B · 2020Article
- Review
- Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12).Breast (Edinburgh, Scotland) · 2020Article
- Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.Frontiers in oncology · 2020Article
- BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.Cancer research and treatment · 2019Observational
- Outcome of Omani Women with Breast Cancer-associated Brain Metastases Experience from a University Hospital.Oman medical journal · 2019Article
- Systemic Therapy of Central Nervous System Metastases of Breast Cancer.Current oncology reports · 2019Review
- Management of Brain Metastases in the New Era of Checkpoint Inhibition.Current neurology and neuroscience reports · 2018Review
- The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation.Journal of neuro-oncology · 2018Article
- Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis.Journal of neuro-oncology · 2018Article
- Targeted Treatment of Brain Metastases.Current neurology and neuroscience reports · 2017Review
- Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer.Chronic diseases and translational medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Asia, large-scale studies on anti-HER2 treatment in HER2-positive breast cancer patients with brain metastases are limited. We studied the treatment patterns of these patients in Asia to evaluate the impact of anti-HER2 treatment on the time to occurrence of brain metastases (TTBM) and survival after brain metastasis (BM).
methodsA retrospective study of HER2-positive breast cancer patients diagnosed with BM between January 2006 and December 2008 in six Asian countries was conducted. Demographics, tumour characteristics, treatment details, and events dates were collected from medical records.
resultsData from 280 patients were analysed. Before BM, 63% received anti-HER2 treatment. These patients had significantly longer TTBM than those without anti-HER2 treatment (median 33 vs 19 months; P<0.002). After BM, 93% received radiotherapy, 57% received chemotherapy, and 41% received anti-HER2 treatment (trastuzumab and/or lapatinib). Use of both anti-HER2 agents, primarily sequentially, after BM demonstrated the longest survival after BM and was associated with a significant survival benefit over no anti-HER2 treatment (median 26 vs 6 months; hazard ratio 0.37; 95% CI 0.19-0.72).
conclusionAnti-HER2 treatment before BM was associated with longer TTBM. Anti-HER2 treatment after BM was associated with a survival benefit, especially when both trastuzumab and lapatinib were utilised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.